US2681582019 - Common Stock
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
DVAX earnings call for the period ending December 31, 2023.
Dynavax reported better-than-expected Q4 earnings with a beat in EPS and revenue.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
Executive changes and a bullish analyst take combined to boost sentiment on the company.
Analyst stock picks for outsized growth potential mean these companies should handily outperform the market averages.
Dynavax Technologies reports strong growth in Q4 2023 with HEPLISAV-B vaccine revenue of $51M, representing a YoY increase of 46%.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
DVAX earnings call for the period ending September 30, 2023.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84.
DVAX earnings call for the period ending June 30, 2023.
Dynavax press release (DVAX): Q2 GAAP EPS of $0.03 beats by $0.12.Revenue of $60.25M (-76.5% Y/Y) beats by $11.87M.2023 FINANCIAL GUIDANCEFull year 2023 financial guidance has...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative...
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.
/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative...